Regeneron Pharmaceuticals, Inc. REGN
788.04
(7.98)
(1.00%)
as of 25 Sep
- Market cap
- $81.3B
- P/E
- 18.8×
Follow REGN
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Regeneron Pharmaceuticals, Inc. (REGN) Free cash flow margin
Regeneron Pharmaceuticals, Inc.'s free cash flow margin over the twelve months to 30 June 2026 was 23.0%, down 3.2 percentage points from fiscal 2025 (26.3%). Over the past ten years it has ranged from 15.9% (fiscal 2015) to 40.6% (fiscal 2021); the current reading is higher than 55% of that period. That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Annual
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 26.3% | 1.19 |
| FY2024 | 25.1% | (2.90) |
| FY2023 | 28.0% | 0.05 |
| FY2022 | 27.9% | (12.72) |
| FY2021 | 40.6% | 17.05 |
| FY2020 | 23.6% | (6.93) |
| FY2019 | 30.5% | (4.70) |
| FY2018 | 35.2% | 17.59 |
| FY2017 | 17.6% | (2.42) |
| FY2016 | 20.0% | 4.13 |
Against its own ten years
Low 15.9%
High 40.6%
Ten-year median
26.3%
Current reading's percentile
55
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| RPRX Royalty Pharma PLC compare | 51.7% |
| VRTX Vertex Pharmaceuticals Incorporated compare | 30.2% |
| ARGX argenex SE compare | 25.9% |
| REGN Regeneron Pharmaceuticals, Inc. | 23.0% |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 21.7% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 17.1% |
| RVMD Revolution Medicines, Inc. compare | 0.00% |
| MRNA Moderna, Inc. compare | −55.8% |
| INSM Insmed, Inc. compare | −71.0% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on REGN
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement